I don't think we'll see too many surprises on the downside, as we're really in bargain basement territory here.
I think a lot of companies have already put expectations so low they haven't set them up for those missteps. Last year [they] really set themselves up for a fall.
I'm very pleased. My boys worked hard, and even though they got down 1-0 early, they worked very hard to come back and get the win.
In the first few games, we've found a lot of hard work and a lot of dedication.
It's actually been really great. The kids are fun to work with and the kids actually do listen to what I say. They show me a lot of respect me and I give it back.
The chronic pain market will likely undergo a major sea change over the next few years and there are significant investment opportunities yet to be recognized.
This slowdown is expected because they are exhausting their cost-savings from the merger. But their earnings growth in 2003 and beyond will still be above most of their peers', thanks to strong drug sales.
We want to get people excited [about VCP]. And we want to encourage researchers to focus on things important to our clients.
We want to get people excited about VCP. And we want to encourage researchers to focus on things important to our clients.
With AHP we'll be looking at everything, just like Pfizer.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.